Monoclonal antibodies against the terminal complement components

  • R. Würzner


Classical or alternative pathway activation of the complement system results in the formation of the terminal complement complex (TCC), made up of the components C5, C6, C7, C8 and C9. In this review, the term membrane attack complex (MAC) is used only to describe the C5b-9(m) complex, the potentially membranolytic form of the TCC generated on biological membranes [1]. The term SC5b-9 is used to describe the generally non-lytic form of the TCC, generated in extracellular fluids in the presence of S-protein [2]. A diagram of the structures and assembly of C5–C9 is shown in Figure 1.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bhakdi S, Tranum-Jensen J. Membrane damage by complement. Biochim Biophys Acta 1983; 737: 343–72.PubMedCrossRefGoogle Scholar
  2. 2.
    Podack ER, Müller-Eberhard HJ. Binding of desoxycholate, phosphatidylcholine vesicles, lipoprotein and of the S-protein to complexes of terminal complement components. J Immunol 1978; 121: 1025–30.PubMedGoogle Scholar
  3. 3.
    Dalmasso AP, Falk RJ, Raji L. The pathobiology of the terminal complement complexes. Complement Inflamm 1989; 6: 36–48.PubMedGoogle Scholar
  4. 4.
    Halstensen TS, Mollnes TE, Brandtzaeg P. Terminal complement complex (TCC) and S-protein (vitronectin) on follicular dendritic cells in human lymphoid tissues. Immunology 1988; 65: 193–7.PubMedGoogle Scholar
  5. 5.
    Zwirner J, Felber E, Schmidt P, Riethmuller G, Feucht HE. Complement activation in human lymphoid germinal centres. Immunology 1989; 66: 270–7.PubMedGoogle Scholar
  6. 6.
    Mandel TE, Phipps RP, Abbot A. Tew JG. The folliclar dendritic cell: long-term antigen retention during immunity. Immunol Rev 1980; 53: 29–36.PubMedCrossRefGoogle Scholar
  7. 7.
    Joiner KA, Brown EJ, Frank MM. Complement and bacteria: chemistry and biology in host defense. Ann Rev Immunol 1984; 2: 461–91.CrossRefGoogle Scholar
  8. 8.
    Morgan BP. Complement membrane attack on nucleated cells: resistance, recovery and non-lethal effects. Biochem J 1989; 264: 1–14.PubMedGoogle Scholar
  9. 9.
    Mollnes TE, Lea T, Tschopp J. Activation-dependent epitopes in the terminal complement pathway. Complement Inflamm 1989; 6: 223–35.PubMedGoogle Scholar
  10. 10.
    Baumgarten H, Rommel C, Bieber F, Isemer FE, Schulze M, Götze O. Hemolytically active complement protein C5 can be detected by an immunoassay using two monoclonal antibodies. Immunobiology 1986; 173: 450.Google Scholar
  11. 11.
    Mollnes TE, Klos A, Tschopp J. Identification of a human C5 β-chain epitope exposed in the native complement component but concealed in the SC5b-9 complex. Scand J Immunol 1988; 28: 307–12.PubMedCrossRefGoogle Scholar
  12. 11a.
    Giclas PC, Baker SL, Gillespie ML, Wilcox C. Preparation and characterization of monoclonal antibodies against the fifth component of rabbit complement (C5). J Immunol Methods 1987; 105: 201–9.PubMedCrossRefGoogle Scholar
  13. 12.
    Würzner R, Orren A, Potter P, et al. Functionally active complement proteins C6 and C7 detected in C6- and C7-deficient individuals. Clin Exp Immunol 1991; 83: 340–7.Google Scholar
  14. 13.
    Würzner R, Hobart MJ, Orren A, et al. A novel protein polymorphism of human complement C7 detected by a monoclonal antibody. Immunogenetics 1992; 35: 398–402.PubMedCrossRefGoogle Scholar
  15. 14.
    Abraha A, Morgan BP, Luzio JP. The preparation and characterization of monoclonal antibodies to human complement component C8 and their use in purification of C8 and C8 subunits. Biochem J 1988; 251: 285–92.PubMedGoogle Scholar
  16. 15.
    Doglio LT, Gawryl MS, Lint TF. Analysis of human C8 with monoclonal antibodies. Characterization of a monoclonal antibody that recognises free C8 alpha-gamma subunit. J Immunol 1988; 141: 2079–83.PubMedGoogle Scholar
  17. 16.
    Mollnes TE, Tschopp J. A unique epitope exposed in native complement component C9 and hidden in the terminal CS5b-9 complex enables selective detection and quantification of non-activated C9. J Immunol Methods 1987; 100: 215–21.PubMedCrossRefGoogle Scholar
  18. 17.
    Takata Y, Moriyama T, Fukomori Y, Yoden A, Shima M, Inai S. A biotin-avidin sandwich ELISA for quantification of intact complement component C9. The sera from hereditary C9 deficient individuals completely lack C9. J Immunol Methods 1989; 117: 107–13.PubMedCrossRefGoogle Scholar
  19. 18.
    Zoppi M, Weiss M, Nydegger UE, Hess T, Späth PJ. Recurrent meningitis in a patient with congenital deficiency of the C9 component of complement. First case of C9 deficiency in Europe. Arch Intern Med 1990; 150: 2395–9.PubMedCrossRefGoogle Scholar
  20. 19.
    Laine RO, Tamerius JD, Kolb WP, Esser AF. Epitope mapping and functional characterization of monoclonal anti-C9 antibodies. Complement Inflamm 1989; 6: 358–9.Google Scholar
  21. 20.
    Morgan BP, Sewry CA, Siddle K, Luzio JP, Campbell AK. Immunolocalization of complement component C9 on necrotic and non-necrotic muscle fibres in myositis using monoclonal antibodies: a primary role of complement in autoimmune cell damage. Immunology 1984; 52: 181–8.PubMedGoogle Scholar
  22. 21.
    Kolb WP, Müller-Eberhard HJ. Neoantigens of the membrane attack complex of human complement. Proc Natl Acad Sci USA 1975; 72: 1687–9.PubMedCrossRefGoogle Scholar
  23. 22.
    Bhakdi S, Bjerrum OJ, Rother U, Kniifermann H, Wallach DFH. Immunochemical analyses of membrane-bound complement: detection of the terminal complement complex and its similarity to intrinsic erythrocyte membrane proteins. Biochim Biophys Acta 1975; 406: 21–35.PubMedCrossRefGoogle Scholar
  24. 23.
    Falk RJ, Dalmasso AP, Kim Y, et al. Neoantigen of the polymerized ninth component of complement. Characterization of a monoclonal antibody and immunohistochemical localization in renal disease. J Clin Invest 1983; 72: 560–73.PubMedCrossRefGoogle Scholar
  25. 24.
    Mollnes TE, Lea T, Harboe M, Tschopp J. Monoclonal antibodies recognizing a neoantigen of poly C9 detect the human terminal complement complex in tissue and plasma. Scand J Immunol 1985; 22: 183–96.PubMedCrossRefGoogle Scholar
  26. 25.
    Hugo F, Jenne D, Bhakdi S. Monoclonal antibodies against neoantigens of the terminal C5b-9 complex of human complement. Biosci Rep 1985; 5: 649–58.PubMedCrossRefGoogle Scholar
  27. 26.
    Kolb WP, Morrow PR, Jensen FC, Tamerius JD. Development of a highly sensitive capture EIA for the quantification of the SC5b-9 complex in human plasma using a monoclonal antibody reactive with a poly-C9 neonantigenic determinant. Complement 1988; 5: 213–4.Google Scholar
  28. 26a.
    Kusunoki Y, Takekoshi Y, Nagasawa S. Using polymerized C9 to produce a monoclonal antibody against a neoantigen of the human terminal complement complex. J Pharmacobiodyn 1990; 13: 454–60.PubMedCrossRefGoogle Scholar
  29. 27.
    Würzner R, Schulze M, Happe L, et al. Inhibition of terminal complement complex (TCC) formation and cell lysis by monoclonal antibodies. Complement Inflamm 1991; 8: 328–40.PubMedGoogle Scholar
  30. 28.
    Bhakdi S, Kaflein R, Halstensen TS, Hugo F, Preissner KT, Mollnes TE. Complement S-protein (vitronectin) is associated with cytolytic membrane-bound C5b-9 complexes. Clin Exp Immunol 1988; 74: 459–64.PubMedGoogle Scholar
  31. 29.
    Tschopp J. Ultrastructure of the membrane attack complex of complement. J Biol Chem 1984; 259: 7857–63.PubMedGoogle Scholar
  32. 30.
    Würzner R, Xu H, Franzke A, Schulze M, Peters JH, Götze O. Blood dendritic cells carry terminal complement complexes on their cell surface as detected by newly-developed neoepitope-specific monoclonal antibodies. Immunology 1991; 74: 132–8.PubMedGoogle Scholar
  33. 31.
    Tschopp J, Mollnes TE. Antigenic crossreactivity of the α subunit of the complement component C8 with the cysteine-rich domain shared by complement component C9 and low density lipoprotein receptor. Proc Natl Acad Sci USA 1986; 83: 4223–7.PubMedCrossRefGoogle Scholar
  34. 32.
    Mollnes TE, Lea T, Froland SS, Harboe M. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand J Immunol 1985; 22: 197–202.PubMedCrossRefGoogle Scholar
  35. 33.
    Hugo F, Krämer S, Bhakdi S. Sensitive ELISA for quantitating the terminal membrane C5b-9 and fluid phase SC5b-9 complex of human complement. J Immunol Methods 1987; 99: 243–51.PubMedCrossRefGoogle Scholar
  36. 34.
    Lindholm PF, Benson BA, Raji L, Dalmasso AP. Significance of plasma levels of SC5b-9 and fragments of C3 and C5 in patients undergoing hemodialysis. Complement 1987; 4: 186.Google Scholar
  37. 35.
    Kongsgaard UE, Smith-Erichsen N, Geiran O, Amundsen E, Mollnes TE, Garred P. Different activation patterns in the plasma kallikrein-kinin and complement systems during coronary bypass surgery. Acta Anaesthesiol Scand 1989; 33: 343–7.PubMedCrossRefGoogle Scholar
  38. 36.
    Deppisch R, Schmitt V, Bommer J, Hänsen GM, Ritz E, Rauterberg EW. Fluid phase generation of terminal complement complex as a novel index of bioincompatibility. Kidney Int 1990; 37: 696–706.PubMedCrossRefGoogle Scholar
  39. 37.
    Würzner R, Schuff-Werner P, Franzke A. et al. Complement activation and depletion during LDL-apheresis by Heparin-induced Extracorporeal LDL-Precipitation (HELP). Eur J Clin Invest 1991; 21: 288–94.PubMedCrossRefGoogle Scholar
  40. 38.
    Chenoweth DE, Hugh TE. Demonstration of a specific C5a receptor on intact human polymorphonuclear leucocytes. Proc Natl Acad Sci USA 1978; 75: 3943–7.PubMedCrossRefGoogle Scholar
  41. 39.
    Wetsel RA, Kolb WP. Complement-independent activation of the fifth component (C5) of human complement: limited trypsin digestion resulting in the expression of biologic activity. J Immunol 1982; 128: 2209–16.PubMedGoogle Scholar
  42. 40.
    Vogt W, Damerau B, von-Zabern I, Nolte R, Brunahl D. Non-enzymatic activation of the fifth component of human complement by oxygen radicals. Some properties of the activation product, C5b-like C5. Molec Immunol 1989; 26: 1133–42.CrossRefGoogle Scholar
  43. 41.
    Falk RJ, Jennette JC. Immune complex induced glomerular lesions in C5 sufficient and deficient mice. Kidney Int 1986; 30: 678–86.PubMedCrossRefGoogle Scholar
  44. 42.
    Groggel GC, Adler S, Rennke HG Couser WG, Salant DJ. Role of terminal complement pathway in experimental membranous nephropathy in the rabbit. J Clin Invest 1983; 72: 1948–57.PubMedCrossRefGoogle Scholar
  45. 43.
    Biesecker G, Gomez CM. Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6. J Immunol 1989; 142: 2654–9.PubMedGoogle Scholar
  46. 44.
    Morgan BP, Dankert JR, Esser AF. Recovery of human neutrophils from complement attack: removal of the membrane attack complex by endocytosis and exocytosis. J Immunol 1987; 138: 246–52.PubMedGoogle Scholar
  47. 45.
    Yancey KB. Biological properties of human C5a: selected in vitro and in vivo studies. Clin Exp Immunol 1988; 71: 207–10.PubMedGoogle Scholar
  48. 46.
    Kontermann R, Deppisch R, Rauterberg EW. Several epitopes on native human complement C9 are involved in interaction with the C5b-8 complex and other C9 molecules. Eur J Immunol 1990; 20: 623–8.PubMedCrossRefGoogle Scholar
  49. 47.
    Dankert JR, Essen AF. Proteolytic modification of human complement protein C9: loss of poly (C9) and circular lesion formation without impairment of function. Proc Natl Acad Sci USA 1985; 82: 2128–32.PubMedCrossRefGoogle Scholar
  50. 47a.
    Pramoonjago P, Kinoshita T, Hong K, et al. Bactericidal activity of C9-deficient human serum. J Immunol 1992; 148: 837–43.PubMedGoogle Scholar
  51. 48.
    Tedesco F, Rottini GD, Basaglia M, Roncelli L, Patriarca P. Monoclonal antibodies anti-C8 interfere with the killing of Escherichia coli 0111:B4 by PMN cationic proteins. Complement 1987; 4: 230.Google Scholar
  52. 48a.
    Yoden A, Moriyama T, Inoue K, Inai S. The role of the C9b domain in the binding of C9 molecules to EAC1–8 defined by monoclonal antibodies. J Immunol 1988; 140, 2317–21.PubMedGoogle Scholar
  53. 49.
    Abraha A, Luzio JP. Inhibition of the formation of the complement membrane-attack complex by a monoclonal antibody to the complement component C8α subunit. Biochem J. 1989; 264: 933–6.PubMedGoogle Scholar
  54. 50.
    Stanley KK, Page M, Campbell AK, Luzio JP. A mechanism for the insertion of complement component C9 into target membranes. Molec Immunol 1986; 23: 451–8.CrossRefGoogle Scholar
  55. 51.
    Morgan BP, Luzio JP, Campbell AK. Inhibition of complement-induced [14C] sucrose release by intracellular and extracellular monoclonal antibodies to C9: evidence that C9 is a transmembrane protein. Biochem Biophys Res Comm 1984; 118: 616–22.PubMedCrossRefGoogle Scholar
  56. 51a.
    Zalman LS, Müller-Eberhard HJ. Comparison of channels formed by poly C9, C5b-8 and the membrane attack complex of complement. Molec Immunol 1990; 27: 533–7.CrossRefGoogle Scholar
  57. 52.
    Dalmasso AP, Benson BA, Falk RJ. Complement channels in membranes: inhibition with a monoclonal antibody to a neoantigen of polymerized C9. Biochem Biophys Res Comm 1984; 125: 1013–9.PubMedCrossRefGoogle Scholar
  58. 53.
    Zeitz HJ, Zeff RA, Gewurz H, Lint TF. Decreased C5b67-inhibitor activity in two families with hereditary functional deficiency of the eighth component of complement. J Immunol 1983; 130: 2809–13.PubMedGoogle Scholar
  59. 54.
    Jenne D, Stanley K. Molecular cloning of S-protein, a link between complement, coagulation and cell-substrate adhesion. EMBO J 1985; 4: 3153–7.PubMedGoogle Scholar
  60. 55.
    Pytela R, Pierschbacher MD, Ruoslathi E. A 125/115-kDa cell surface receptor specific for vitronectin interacts with the arginine-glycine-aspartic acid adhesion sequence derived from fibronectin. Proc Natl Acad Sci USA 1985; 82: 5766–70.PubMedCrossRefGoogle Scholar
  61. 56.
    Preissner KT, Chatwal GS, Müller-Berghaus G, Blobel H. Specific binding of human complement S-protein/vitronectin to different bacterial species. Complement 1987; 4: 214.Google Scholar
  62. 57.
    Podack ER, Kolb WP, Müller -Eberhard HJ. The C5b-6 complex: formation, isolation, and inhibition of its activity by lipoprotein and the S-protein of human serum. J Immunol 1978; 120: 1841–8.PubMedGoogle Scholar
  63. 58.
    Podack ER, Preissner KT, Müller -Eberhard HJ. Inhibition of C9 polymerization within the SC5b-9 complex of complement by S-protein. Acta Pathol Microbiol Immunol Scand Suppl 1984; 284: 89–96.PubMedGoogle Scholar
  64. 59.
    Tschopp J, Masson D, Schäfer S, Peitsch M, Preissner KT. The heparin binding domain of S-protein vitronectin binds to complement components C7, C8, C9 and perforin from cytolytic T-cells and inhibits their lytic activities. Biochemistry 1988; 27: 4103–9.PubMedCrossRefGoogle Scholar
  65. 60.
    Lint TF, Behrends CL, Gewurz H. Serum lipoproteins and C567-INH activity. J Immunol 1977; 119:883–8.PubMedGoogle Scholar
  66. 61.
    Tschopp J, Masson D. Inhibition of the lytic activity of perforin (cytolysin) and of late complement components by proteoglycans. Molec Immunol 1987; 24: 907–13.CrossRefGoogle Scholar
  67. 62.
    Zalman L, Wood M, Müller-Eberhard HJ. Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels. Proc Natl Acad Sci USA 1986; 83: 6975–9.PubMedCrossRefGoogle Scholar
  68. 63.
    Schönermark S, Rauterberg EW, Shin ML, Löke S, Roelke D, Hänsen GM. Homologous species restriction in lysis of human erythrocytes: a membrane derived protein with C8-binding capacity functions as an inhibitor. J Immunol 1986; 136: 1772–6.PubMedGoogle Scholar
  69. 64.
    Watts MJ, Dankert JR, Morgan BP. Isolation and charaterization of a membrane-attack-complex-inhibiting protein present in human serum and other biological fluids. Biochem J 1990; 265: 471–7.PubMedGoogle Scholar
  70. 65.
    Sugita Y, Nakano Y, Tomita M. Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels. J Biochem 1988; 104: 633–7.PubMedGoogle Scholar
  71. 66.
    Okada N, Harada R, Fujita T, Okada H. A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement. Int Immunol 1989; 1: 205–8.PubMedCrossRefGoogle Scholar
  72. 67.
    Davies A, Simmons DL, Hale C, et al. CD 59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement attack complex on homologous cells. J Exp Med 1989; 127: 637–54.CrossRefGoogle Scholar
  73. 68.
    Holguin MH, Frederick CR, Bernshaw NJ, Wilcox LA, Parker CJ. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal noctural hemoglobinuria. J Clin Invest 1989; 84: 7–17.PubMedCrossRefGoogle Scholar
  74. 69.
    Whitlow MB, Iida K, Stefanova I, Bernard A, Nussenzweig V. H19, a surface membrane molecule involved in T-cell activation, inhibits channel formation by human complement. Cell Immunol 1990; 126: 176–84.PubMedCrossRefGoogle Scholar
  75. 70.
    Rollins SA, Sims PJ. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol 1990; 144: 3478–83.PubMedGoogle Scholar
  76. 71.
    Meri S, Morgan BP, Davies A, et al. Human protectin (CD59), a 18,000–20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 1990; 71: 1–9.PubMedGoogle Scholar
  77. 72.
    Dave SJ, Sodetz JM. Regulation of the membrane attack complex of complement. Evidence that C8 gamma is not the target of homologous restriction factors. J Immunol 1990; 144: 3087–90.PubMedGoogle Scholar
  78. 73.
    Okada N, Harada R, Fujita T, Okada H. Monoclonal antibodies capable of causing hemolysis of neuraminidase-treated human erythrocytes by homologous complement. J Immunol 1989; 143: 2262–6.PubMedGoogle Scholar
  79. 74.
    Choi NH, Mazda T, Tomita M. A serum protein SP40, 40 modulates the formation of membrane attack complex of complement on erythrocytes. Molec Immunol 1989; 26: 835–40.CrossRefGoogle Scholar
  80. 75.
    Jenne DE, Tschopp J. Molecular structure and functional characterization of a human complement cytolysis inhibitor found in blood and seminal plasma: identity to sulfated glycoprotein 2, a constitutent of rat testis fluid. Proc Natl Acad Sci USA 1989; 86: 7123–7.PubMedCrossRefGoogle Scholar
  81. 75a.
    Choi NH, Tobe T, Hara K, Yoshida H, Tomita M. Sandwich ELISA assay for quantitative measurement of SP-40, 40 in seminal plasma and serum. J Immunol Methods 1990; 131: 159–63.PubMedCrossRefGoogle Scholar
  82. 76.
    Sundsmo JS, Götze O. Human monocyte spreading induced by activated factor B of the complement alternative pathway: different effects of Fab’ and F(ab’)2 antibody fragments directed to C5, C6 and C7. Cell Immunol 1983; 77: 176–86.PubMedCrossRefGoogle Scholar
  83. 77.
    Okada H, Nagami Y, Takahashi K, et al. 20KDa homologous restriction factor of complement resembles T cell activating protein. Biochem Biophys Res Commun 1989; 162: 1553–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1993

Authors and Affiliations

  • R. Würzner

There are no affiliations available

Personalised recommendations